Tan et al. (2014) [23] | Hotu et al. (2010) [22] | Shephard et al. (2006) [27] | Kondalsamy-Chennakesavan (2003) [26] #1 | Kondalsamy-Chennakesavan (2003) [26] #2 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Outcome measure (n) | Baseline (n = 43) | 17mths (n = 39) | Baseline (n = 52) | 12mths (n = 36) | Baseline CC(n = 33) UC(n = 32) | 12mths (n = 30) (n = 28) | Baseline | 15mths | Baseline MRTP (n = 149) CCT (n = 89) | 30mths (n = 149) (n = 89) | Pre-(n = 101) | Post-(n = 101) |
Systolic Blood Pressure mmHg(SD) | 137 (17) | 126 (16)* | 153 (15) | 131 (11)* | 161 (20) 161 (20) | 140 (19) 149 (23)** | 151 (18) | 137 (18)* | 132 (22) 126 (20) | 123 (16) 128 (16)** | 124 (14) | 129 (15) |
Median ACR mg/mmol(IQR) #g/day(IQR) | 126 (65–194) | 51 (20–97) | 34.9 (14.2–150.9) Mean:c 134.5 (286.5) | Median not reported Mean: 44.7 (76)* | 3.3 (1.5–3.2) 1.6 (0.9–4.0) | 2 (0.5–3.8) 3.3 (1.5–5.3)** | 5.7 (1.2–15.2) | 4.3 (1.3–16.7) | NA | NA | NA | NA |
eGFR | 68 (50–81) | 63.1 (42–73)* | 63.1 (20.2) | 60.8 (18.2) | 39 (14) 36 (15) | 41 (18) 33 (17) | 110 | 118* | NA | NA | NA | NA |
HbA1c %(SD) | 9.6 (24) | 8.6 (20)* | 9.1 (14)b | 8.0 (9)b* | 8.3 (9)a 8.5 (11)a | 8.0 (10)a 7.9 (9)a | NA | NA | NA | NA | NA | NA |